/Companies

Curevo Vaccine

Unicorn exit · $1.5BAcquired

Bothell, US · Founded 2017 · 43 employees on LinkedIn · 9 known investors

Find your way into Curevo Vaccine

Sign up to see every warm intro you have to Curevo Vaccine

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Curevo Vaccine team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Acquired by Eli Lilly and Company May 2026 · $1.5B (up to $1.5 billion cash, including upfront and milestone payment) · source ↗

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases. It operates in clinical-stage vaccine development.

Founders & leadership

GSGeorge Simeon
George SimeonCEOGeorge Simeon held executive roles at Johnson & Johnson, Novartis, and SK Telecom before serving as CEO of Curevo Vaccine, where he led the company through clinical development and its acquisition by Eli Lilly; he brings over 30 years of healthcare industry experience across biotechnology, pharmaceuticals, medical devices, and diagnostics.
GS
Gregory S. CurhanCFO
GDGuy De La Rosa
Guy De La RosaCMOGuy De La Rosa is Chief Medical Officer at Curevo Vaccine, a clinical-stage biotech company developing non-mRNA vaccines for infectious diseases. He is board-certified in internal medicine and infectious diseases, with experience in clinical research and medical affairs in the pharmaceutical industry.

Investors · 9

Also in the syndicate · 2

GC BiopharmaHBM Healthcare Investors

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Frequently asked questions

What does Curevo Vaccine do?
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases. It operates in clinical-stage vaccine development.
Who are Curevo Vaccine's investors?
Curevo Vaccine's investors include Adjuvant Capital, HBM Healthcare Investments, Medicxi, OrbiMed, RA Capital, Sanofi Ventures, Janus Henderson Investors.
Where is Curevo Vaccine headquartered?
Curevo Vaccine is headquartered in Bothell, US.